Watch Demo

Global Breast Cancer Liquid Biopsy Industry

Global Breast Cancer Liquid Biopsy Industry

  • Publish Date:October 2022

  • Number of Pages:89

  • Report ID:6030988

  • Format:PDF

  • Publisher:Global Industry Analysts

$ 5600

Summary

Abstract:

What’s New for 2022?

Global competitiveness and key competitor percentage market shares
Market presence across multiple geographies - Strong/Active/Niche/Trivial
Online interactive peer-to-peer collaborative bespoke updates
Access to our digital archives and MarketGlass Research Platform
Complimentary updates for one year

Global Breast Cancer Liquid Biopsy Market to Reach $489.6 Million by 2027

In the changed post COVID-19 business landscape, the global market for Breast Cancer Liquid Biopsy estimated at US$107.6 Million in the year 2020, is projected to reach a revised size of US$489.6 Million by 2027, growing at a CAGR of 24.2% over the analysis period 2020-2027. Reagent Kits, one of the segments analyzed in the report, is projected to record a 24.8% CAGR and reach US$366.7 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Instruments segment is readjusted to a revised 23.7% CAGR for the next 7-year period.

The U.S. Market is Estimated at $31.5 Million, While China is Forecast to Grow at 23.3% CAGR

The Breast Cancer Liquid Biopsy market in the U.S. is estimated at US$31.5 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$84.1 Million by the year 2027 trailing a CAGR of 23.3% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 22% and 21.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 18.1% CAGR.

Services Segment to Record 18.1% CAGR

In the global Services segment, USA, Canada, Japan, China and Europe will drive the 18.1% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$5.8 Million in the year 2020 will reach a projected size of US$18.2 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.

Select Competitors (Total 34 Featured) -
Biodesix, Inc.
Bio-Rad Laboratories
Cynvenio Biosystems, Inc.
Fluxion Biosciences, Inc.
Genomic Health, Inc.
Guardant Health, Inc.
Illumina
Isogen Life Science B.V.
Menarini Silicon Biosystems
Myriad Genetics

Table of contents

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Breast Cancer Liquid Biopsy - Global Key Competitors Percentage
Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Breast Cancer Liquid Biopsy Market Analysis of
Annual Sales in US$ for Years 2012 through 2027

Table 2: World Recent Past, Current & Future Analysis for
Breast Cancer Liquid Biopsy by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ for Years 2020
through 2027 and % CAGR

Table 3: World Historic Review for Breast Cancer Liquid Biopsy
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 4: World 15-Year Perspective for Breast Cancer Liquid
Biopsy by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets for Years 2012, 2021 & 2027

Table 5: World Recent Past, Current & Future Analysis for
Diagnostics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ for Years 2020 through 2027 and
% CAGR

Table 6: World Historic Review for Diagnostics by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ for Years 2012 through 2019 and % CAGR

Table 7: World 15-Year Perspective for Diagnostics by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 8: World Recent Past, Current & Future Analysis for
Prognostics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ for Years 2020 through 2027 and
% CAGR

Table 9: World Historic Review for Prognostics by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ for Years 2012 through 2019 and % CAGR

Table 10: World 15-Year Perspective for Prognostics by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 11: World Recent Past, Current & Future Analysis for Risk
Assessment by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ for Years 2020 through 2027 and
% CAGR

Table 12: World Historic Review for Risk Assessment by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 13: World 15-Year Perspective for Risk Assessment by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 14: World Recent Past, Current & Future Analysis for
Reagent Kits by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ for Years 2020 through 2027 and
% CAGR

Table 15: World Historic Review for Reagent Kits by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ for Years 2012 through 2019 and % CAGR

Table 16: World 15-Year Perspective for Reagent Kits by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 17: World Recent Past, Current & Future Analysis for
Instruments by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ for Years 2020 through 2027 and
% CAGR

Table 18: World Historic Review for Instruments by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ for Years 2012 through 2019 and % CAGR

Table 19: World 15-Year Perspective for Instruments by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 20: World Recent Past, Current & Future Analysis for
Services by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ for Years 2020 through 2027 and
% CAGR

Table 21: World Historic Review for Services by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ for Years 2012 through 2019 and % CAGR

Table 22: World 15-Year Perspective for Services by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2021 & 2027

Table 23: World Recent Past, Current & Future Analysis for
Circulating Tumor Cells by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ for Years 2020
through 2027 and % CAGR

Table 24: World Historic Review for Circulating Tumor Cells by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 25: World 15-Year Perspective for Circulating Tumor Cells
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 26: World Recent Past, Current & Future Analysis for
Extracellular Vesicles by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ for Years 2020
through 2027 and % CAGR

Table 27: World Historic Review for Extracellular Vesicles by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 28: World 15-Year Perspective for Extracellular Vesicles
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 29: World Recent Past, Current & Future Analysis for
Circulating Tumor DNA by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ for Years 2020
through 2027 and % CAGR

Table 30: World Historic Review for Circulating Tumor DNA by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 31: World 15-Year Perspective for Circulating Tumor DNA
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

III. MARKET ANALYSIS

UNITED STATES
Breast Cancer Liquid Biopsy Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in the United States for 2022
(E)
Table 32: USA Recent Past, Current & Future Analysis for Breast
Cancer Liquid Biopsy by Product & Service - Reagent Kits,
Instruments and Services - Independent Analysis of Annual Sales
in US$ for the Years 2020 through 2027 and % CAGR

Table 33: USA Historic Review for Breast Cancer Liquid Biopsy
by Product & Service - Reagent Kits, Instruments and Services
Markets - Independent Analysis of Annual Sales in US$ for Years
2012 through 2019 and % CAGR

Table 34: USA 15-Year Perspective for Breast Cancer Liquid
Biopsy by Product & Service - Percentage Breakdown of Value
Sales for Reagent Kits, Instruments and Services for the Years
2012, 2021 & 2027

Table 35: USA Recent Past, Current & Future Analysis for Breast
Cancer Liquid Biopsy by Application - Diagnostics, Prognostics
and Risk Assessment - Independent Analysis of Annual Sales in
US$ for the Years 2020 through 2027 and % CAGR

Table 36: USA Historic Review for Breast Cancer Liquid Biopsy
by Application - Diagnostics, Prognostics and Risk Assessment
Markets - Independent Analysis of Annual Sales in US$ for Years
2012 through 2019 and % CAGR

Table 37: USA 15-Year Perspective for Breast Cancer Liquid
Biopsy by Application - Percentage Breakdown of Value Sales for
Diagnostics, Prognostics and Risk Assessment for the Years
2012, 2021 & 2027

Table 38: USA Recent Past, Current & Future Analysis for Breast
Cancer Liquid Biopsy by Circulating Biomarker - Circulating
Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA -
Independent Analysis of Annual Sales in US$ for the Years 2020
through 2027 and % CAGR

Table 39: USA Historic Review for Breast Cancer Liquid Biopsy
by Circulating Biomarker - Circulating Tumor Cells,
Extracellular Vesicles and Circulating Tumor DNA Markets -
Independent Analysis of Annual Sales in US$ for Years 2012
through 2019 and % CAGR

Table 40: USA 15-Year Perspective for Breast Cancer Liquid
Biopsy by Circulating Biomarker - Percentage Breakdown of Value
Sales for Circulating Tumor Cells, Extracellular Vesicles and
Circulating Tumor DNA for the Years 2012, 2021 & 2027

CANADA
Table 41: Canada Recent Past, Current & Future Analysis for
Breast Cancer Liquid Biopsy by Product & Service - Reagent
Kits, Instruments and Services - Independent Analysis of Annual
Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 42: Canada Historic Review for Breast Cancer Liquid
Biopsy by Product & Service - Reagent Kits, Instruments and
Services Markets - Independent Analysis of Annual Sales in US$
for Years 2012 through 2019 and % CAGR

Table 43: Canada 15-Year Perspective for Breast Cancer Liquid
Biopsy by Product & Service - Percentage Breakdown of Value
Sales for Reagent Kits, Instruments and Services for the Years
2012, 2021 & 2027

Table 44: Canada Recent Past, Current & Future Analysis for
Breast Cancer Liquid Biopsy by Application - Diagnostics,
Prognostics and Risk Assessment - Independent Analysis of
Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 45: Canada Historic Review for Breast Cancer Liquid
Biopsy by Application - Diagnostics, Prognostics and Risk
Assessment Markets - Independent Analysis of Annual Sales in
US$ for Years 2012 through 2019 and % CAGR

Table 46: Canada 15-Year Perspective for Breast Cancer Liquid
Biopsy by Application - Percentage Breakdown of Value Sales for
Diagnostics, Prognostics and Risk Assessment for the Years
2012, 2021 & 2027

Table 47: Canada Recent Past, Current & Future Analysis for
Breast Cancer Liquid Biopsy by Circulating Biomarker -
Circulating Tumor Cells, Extracellular Vesicles and Circulating
Tumor DNA - Independent Analysis of Annual Sales in US$ for the
Years 2020 through 2027 and % CAGR

Table 48: Canada Historic Review for Breast Cancer Liquid
Biopsy by Circulating Biomarker - Circulating Tumor Cells,
Extracellular Vesicles and Circulating Tumor DNA Markets -
Independent Analysis of Annual Sales in US$ for Years 2012
through 2019 and % CAGR

Table 49: Canada 15-Year Perspective for Breast Cancer Liquid
Biopsy by Circulating Biomarker - Percentage Breakdown of Value
Sales for Circulating Tumor Cells, Extracellular Vesicles and
Circulating Tumor DNA for the Years 2012, 2021 & 2027

JAPAN
Breast Cancer Liquid Biopsy Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in Japan for 2022 (E)
Table 50: Japan Recent Past, Current & Future Analysis for
Breast Cancer Liquid Biopsy by Product & Service - Reagent
Kits, Instruments and Services - Independent Analysis of Annual
Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 51: Japan Historic Review for Breast Cancer Liquid Biopsy
by Product & Service - Reagent Kits, Instruments and Services
Markets - Independent Analysis of Annual Sales in US$ for Years
2012 through 2019 and % CAGR

Table 52: Japan 15-Year Perspective for Breast Cancer Liquid
Biopsy by Product & Service - Percentage Breakdown of Value
Sales for Reagent Kits, Instruments and Services for the Years
2012, 2021 & 2027

Table 53: Japan Recent Past, Current & Future Analysis for
Breast Cancer Liquid Biopsy by Application - Diagnostics,
Prognostics and Risk Assessment - Independent Analysis of
Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 54: Japan Historic Review for Breast Cancer Liquid Biopsy
by Application - Diagnostics, Prognostics and Risk Assessment
Markets - Independent Analysis of Annual Sales in US$ for Years
2012 through 2019 and % CAGR

Table 55: Japan 15-Year Perspective for Breast Cancer Liquid
Biopsy by Application - Percentage Breakdown of Value Sales for
Diagnostics, Prognostics and Risk Assessment for the Years
2012, 2021 & 2027

Table 56: Japan Recent Past, Current & Future Analysis for
Breast Cancer Liquid Biopsy by Circulating Biomarker -
Circulating Tumor Cells, Extracellular Vesicles and Circulating
Tumor DNA - Independent Analysis of Annual Sales in US$ for the
Years 2020 through 2027 and % CAGR

Table 57: Japan Historic Review for Breast Cancer Liquid Biopsy
by Circulating Biomarker - Circulating Tumor Cells,
Extracellular Vesicles and Circulating Tumor DNA Markets -
Independent Analysis of Annual Sales in US$ for Years 2012
through 2019 and % CAGR

Table 58: Japan 15-Year Perspective for Breast Cancer Liquid
Biopsy by Circulating Biomarker - Percentage Breakdown of Value
Sales for Circulating Tumor Cells, Extracellular Vesicles and
Circulating Tumor DNA for the Years 2012, 2021 & 2027

CHINA
Breast Cancer Liquid Biopsy Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in China for 2022 (E)
Table 59: China Recent Past, Current & Future Analysis for
Breast Cancer Liquid Biopsy by Product & Service - Reagent
Kits, Instruments and Services - Independent Analysis of Annual
Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 60: China Historic Review for Breast Cancer Liquid Biopsy
by Product & Service - Reagent Kits, Instruments and Services
Markets - Independent Analysis of Annual Sales in US$ for Years
2012 through 2019 and % CAGR

Table 61: China 15-Year Perspective for Breast Cancer Liquid
Biopsy by Product & Service - Percentage Breakdown of Value
Sales for Reagent Kits, Instruments and Services for the Years
2012, 2021 & 2027

Table 62: China Recent Past, Current & Future Analysis for
Breast Cancer Liquid Biopsy by Application - Diagnostics,
Prognostics and Risk Assessment - Independent Analysis of
Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 63: China Historic Review for Breast Cancer Liquid Biopsy
by Application - Diagnostics, Prognostics and Risk Assessment
Markets - Independent Analysis of Annual Sales in US$ for Years
2012 through 2019 and % CAGR

Table 64: China 15-Year Perspective for Breast Cancer Liquid
Biopsy by Application - Percentage Breakdown of Value Sales for
Diagnostics, Prognostics and Risk Assessment for the Years
2012, 2021 & 2027

Table 65: China Recent Past, Current & Future Analysis for
Breast Cancer Liquid Biopsy by Circulating Biomarker -
Circulating Tumor Cells, Extracellular Vesicles and Circulating
Tumor DNA - Independent Analysis of Annual Sales in US$ for the
Years 2020 through 2027 and % CAGR

Table 66: China Historic Review for Breast Cancer Liquid Biopsy
by Circulating Biomarker - Circulating Tumor Cells,
Extracellular Vesicles and Circulating Tumor DNA Markets -
Independent Analysis of Annual Sales in US$ for Years 2012
through 2019 and % CAGR

Table 67: China 15-Year Perspective for Breast Cancer Liquid
Biopsy by Circulating Biomarker - Percentage Breakdown of Value
Sales for Circulating Tumor Cells, Extracellular Vesicles and
Circulating Tumor DNA for the Years 2012, 2021 & 2027

EUROPE
Breast Cancer Liquid Biopsy Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in Europe for 2022 (E)
Table 68: Europe Recent Past, Current & Future Analysis for
Breast Cancer Liquid Biopsy by Geographic Region - France,
Germany, Italy, UK and Rest of Europe Markets - Independent
Analysis of Annual Sales in US$ for Years 2020 through 2027 and
% CAGR

Table 69: Europe Historic Review for Breast Cancer Liquid
Biopsy by Geographic Region - France, Germany, Italy, UK and
Rest of Europe Markets - Independent Analysis of Annual Sales
in US$ for Years 2012 through 2019 and % CAGR

Table 70: Europe 15-Year Perspective for Breast Cancer Liquid
Biopsy by Geographic Region - Percentage Breakdown of Value
Sales for France, Germany, Italy, UK and Rest of Europe Markets
for Years 2012, 2021 & 2027

Table 71: Europe Recent Past, Current & Future Analysis for
Breast Cancer Liquid Biopsy by Product & Service - Reagent
Kits, Instruments and Services - Independent Analysis of Annual
Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 72: Europe Historic Review for Breast Cancer Liquid
Biopsy by Product & Service - Reagent Kits, Instruments and
Services Markets - Independent Analysis of Annual Sales in US$
for Years 2012 through 2019 and % CAGR

Table 73: Europe 15-Year Perspective for Breast Cancer Liquid
Biopsy by Product & Service - Percentage Breakdown of Value
Sales for Reagent Kits, Instruments and Services for the Years
2012, 2021 & 2027

Table 74: Europe Recent Past, Current & Future Analysis for
Breast Cancer Liquid Biopsy by Application - Diagnostics,
Prognostics and Risk Assessment - Independent Analysis of
Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 75: Europe Historic Review for Breast Cancer Liquid
Biopsy by Application - Diagnostics, Prognostics and Risk
Assessment Markets - Independent Analysis of Annual Sales in
US$ for Years 2012 through 2019 and % CAGR

Table 76: Europe 15-Year Perspective for Breast Cancer Liquid
Biopsy by Application - Percentage Breakdown of Value Sales for
Diagnostics, Prognostics and Risk Assessment for the Years
2012, 2021 & 2027

Table 77: Europe Recent Past, Current & Future Analysis for
Breast Cancer Liquid Biopsy by Circulating Biomarker -
Circulating Tumor Cells, Extracellular Vesicles and Circulating
Tumor DNA - Independent Analysis of Annual Sales in US$ for the
Years 2020 through 2027 and % CAGR

Table 78: Europe Historic Review for Breast Cancer Liquid
Biopsy by Circulating Biomarker - Circulating Tumor Cells,
Extracellular Vesicles and Circulating Tumor DNA Markets -
Independent Analysis of Annual Sales in US$ for Years 2012
through 2019 and % CAGR

Table 79: Europe 15-Year Perspective for Breast Cancer Liquid
Biopsy by Circulating Biomarker - Percentage Breakdown of Value
Sales for Circulating Tumor Cells, Extracellular Vesicles and
Circulating Tumor DNA for the Years 2012, 2021 & 2027

FRANCE
Breast Cancer Liquid Biopsy Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in France for 2022 (E)
Table 80: France Recent Past, Current & Future Analysis for
Breast Cancer Liquid Biopsy by Product & Service - Reagent
Kits, Instruments and Services - Independent Analysis of Annual
Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 81: France Historic Review for Breast Cancer Liquid
Biopsy by Product & Service - Reagent Kits, Instruments and
Services Markets - Independent Analysis of Annual Sales in US$
for Years 2012 through 2019 and % CAGR

Table 82: France 15-Year Perspective for Breast Cancer Liquid
Biopsy by Product & Service - Percentage Breakdown of Value
Sales for Reagent Kits, Instruments and Services for the Years
2012, 2021 & 2027

Table 83: France Recent Past, Current & Future Analysis for
Breast Cancer Liquid Biopsy by Application - Diagnostics,
Prognostics and Risk Assessment - Independent Analysis of
Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 84: France Historic Review for Breast Cancer Liquid
Biopsy by Application - Diagnostics, Prognostics and Risk
Assessment Markets - Independent Analysis of Annual Sales in
US$ for Years 2012 through 2019 and % CAGR

Table 85: France 15-Year Perspective for Breast Cancer Liquid
Biopsy by Application - Percentage Breakdown of Value Sales for
Diagnostics, Prognostics and Risk Assessment for the Years
2012, 2021 & 2027

Table 86: France Recent Past, Current & Future Analysis for
Breast Cancer Liquid Biopsy by Circulating Biomarker -
Circulating Tumor Cells, Extracellular Vesicles and Circulating
Tumor DNA - Independent Analysis of Annual Sales in US$ for the
Years 2020 through 2027 and % CAGR

Table 87: France Historic Review for Breast Cancer Liquid
Biopsy by Circulating Biomarker - Circulating Tumor Cells,
Extracellular Vesicles and Circulating Tumor DNA Markets -
Independent Analysis of Annual Sales in US$ for Years 2012
through 2019 and % CAGR

Table 88: France 15-Year Perspective for Breast Cancer Liquid
Biopsy by Circulating Biomarker - Percentage Breakdown of Value
Sales for Circulating Tumor Cells, Extracellular Vesicles and
Circulating Tumor DNA for the Years 2012, 2021 & 2027

GERMANY
Breast Cancer Liquid Biopsy Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in Germany for 2022 (E)
Table 89: Germany Recent Past, Current & Future Analysis for
Breast Cancer Liquid Biopsy by Product & Service - Reagent
Kits, Instruments and Services - Independent Analysis of Annual
Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 90: Germany Historic Review for Breast Cancer Liquid
Biopsy by Product & Service - Reagent Kits, Instruments and
Services Markets - Independent Analysis of Annual Sales in US$
for Years 2012 through 2019 and % CAGR

Table 91: Germany 15-Year Perspective for Breast Cancer Liquid
Biopsy by Product & Service - Percentage Breakdown of Value
Sales for Reagent Kits, Instruments and Services for the Years
2012, 2021 & 2027

Table 92: Germany Recent Past, Current & Future Analysis for
Breast Cancer Liquid Biopsy by Application - Diagnostics,
Prognostics and Risk Assessment - Independent Analysis of
Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 93: Germany Historic Review for Breast Cancer Liquid
Biopsy by Application - Diagnostics, Prognostics and Risk
Assessment Markets - Independent Analysis of Annual Sales in
US$ for Years 2012 through 2019 and % CAGR

Table 94: Germany 15-Year Perspective for Breast Cancer Liquid
Biopsy by Application - Percentage Breakdown of Value Sales for
Diagnostics, Prognostics and Risk Assessment for the Years
2012, 2021 & 2027

Table 95: Germany Recent Past, Current & Future Analysis for
Breast Cancer Liquid Biopsy by Circulating Biomarker -
Circulating Tumor Cells, Extracellular Vesicles and Circulating
Tumor DNA - Independent Analysis of Annual Sales in US$ for the
Years 2020 through 2027 and % CAGR

Table 96: Germany Historic Review for Breast Cancer Liquid
Biopsy by Circulating Biomarker - Circulating Tumor Cells,
Extracellular Vesicles and Circulating Tumor DNA Markets -
Independent Analysis of Annual Sales in US$ for Years 2012
through 2019 and % CAGR

Table 97: Germany 15-Year Perspective for Breast Cancer Liquid
Biopsy by Circulating Biomarker - Percentage Breakdown of Value
Sales for Circulating Tumor Cells, Extracellular Vesicles and
Circulating Tumor DNA for the Years 2012, 2021 & 2027

ITALY
Table 98: Italy Recent Past, Current & Future Analysis for
Breast Cancer Liquid Biopsy by Product & Service - Reagent
Kits, Instruments and Services - Independent Analysis of Annual
Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 99: Italy Historic Review for Breast Cancer Liquid Biopsy
by Product & Service - Reagent Kits, Instruments and Services
Markets - Independent Analysis of Annual Sales in US$ for Years
2012 through 2019 and % CAGR

Table 100: Italy 15-Year Perspective for Breast Cancer Liquid
Biopsy by Product & Service - Percentage Breakdown of Value
Sales for Reagent Kits, Instruments and Services for the Years
2012, 2021 & 2027

Table 101: Italy Recent Past, Current & Future Analysis for
Breast Cancer Liquid Biopsy by Application - Diagnostics,
Prognostics and Risk Assessment - Independent Analysis of
Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 102: Italy Historic Review for Breast Cancer Liquid
Biopsy by Application - Diagnostics, Prognostics and Risk
Assessment Markets - Independent Analysis of Annual Sales in
US$ for Years 2012 through 2019 and % CAGR

Table 103: Italy 15-Year Perspective for Breast Cancer Liquid
Biopsy by Application - Percentage Breakdown of Value Sales for
Diagnostics, Prognostics and Risk Assessment for the Years
2012, 2021 & 2027

Table 104: Italy Recent Past, Current & Future Analysis for
Breast Cancer Liquid Biopsy by Circulating Biomarker -
Circulating Tumor Cells, Extracellular Vesicles and Circulating
Tumor DNA - Independent Analysis of Annual Sales in US$ for the
Years 2020 through 2027 and % CAGR

Table 105: Italy Historic Review for Breast Cancer Liquid
Biopsy by Circulating Biomarker - Circulating Tumor Cells,
Extracellular Vesicles and Circulating Tumor DNA Markets -
Independent Analysis of Annual Sales in US$ for Years 2012
through 2019 and % CAGR

Table 106: Italy 15-Year Perspective for Breast Cancer Liquid
Biopsy by Circulating Biomarker - Percentage Breakdown of Value
Sales for Circulating Tumor Cells, Extracellular Vesicles and
Circulating Tumor DNA for the Years 2012, 2021 & 2027

UNITED KINGDOM
Breast Cancer Liquid Biopsy Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in the United Kingdom for 2022
(E)
Table 107: UK Recent Past, Current & Future Analysis for Breast
Cancer Liquid Biopsy by Product & Service - Reagent Kits,
Instruments and Services - Independent Analysis of Annual Sales
in US$ for the Years 2020 through 2027 and % CAGR

Table 108: UK Historic Review for Breast Cancer Liquid Biopsy
by Product & Service - Reagent Kits, Instruments and Services
Markets - Independent Analysis of Annual Sales in US$ for Years
2012 through 2019 and % CAGR

Table 109: UK 15-Year Perspective for Breast Cancer Liquid
Biopsy by Product & Service - Percentage Breakdown of Value
Sales for Reagent Kits, Instruments and Services for the Years
2012, 2021 & 2027

Table 110: UK Recent Past, Current & Future Analysis for Breast
Cancer Liquid Biopsy by Application - Diagnostics, Prognostics
and Risk Assessment - Independent Analysis of Annual Sales in
US$ for the Years 2020 through 2027 and % CAGR

Table 111: UK Historic Review for Breast Cancer Liquid Biopsy
by Application - Diagnostics, Prognostics and Risk Assessment
Markets - Independent Analysis of Annual Sales in US$ for Years
2012 through 2019 and % CAGR

Table 112: UK 15-Year Perspective for Breast Cancer Liquid
Biopsy by Application - Percentage Breakdown of Value Sales for
Diagnostics, Prognostics and Risk Assessment for the Years
2012, 2021 & 2027

Table 113: UK Recent Past, Current & Future Analysis for Breast
Cancer Liquid Biopsy by Circulating Biomarker - Circulating
Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA -
Independent Analysis of Annual Sales in US$ for the Years 2020
through 2027 and % CAGR

Table 114: UK Historic Review for Breast Cancer Liquid Biopsy
by Circulating Biomarker - Circulating Tumor Cells,
Extracellular Vesicles and Circulating Tumor DNA Markets -
Independent Analysis of Annual Sales in US$ for Years 2012
through 2019 and % CAGR

Table 115: UK 15-Year Perspective for Breast Cancer Liquid
Biopsy by Circulating Biomarker - Percentage Breakdown of Value
Sales for Circulating Tumor Cells, Extracellular Vesicles and
Circulating Tumor DNA for the Years 2012, 2021 & 2027

REST OF EUROPE
Table 116: Rest of Europe Recent Past, Current & Future
Analysis for Breast Cancer Liquid Biopsy by Product & Service -
Reagent Kits, Instruments and Services - Independent Analysis
of Annual Sales in US$ for the Years 2020 through 2027 and %
CAGR

Table 117: Rest of Europe Historic Review for Breast Cancer
Liquid Biopsy by Product & Service - Reagent Kits, Instruments
and Services Markets - Independent Analysis of Annual Sales in
US$ for Years 2012 through 2019 and % CAGR

Table 118: Rest of Europe 15-Year Perspective for Breast Cancer
Liquid Biopsy by Product & Service - Percentage Breakdown of
Value Sales for Reagent Kits, Instruments and Services for the
Years 2012, 2021 & 2027

Table 119: Rest of Europe Recent Past, Current & Future
Analysis for Breast Cancer Liquid Biopsy by Application -
Diagnostics, Prognostics and Risk Assessment - Independent
Analysis of Annual Sales in US$ for the Years 2020 through 2027
and % CAGR

Table 120: Rest of Europe Historic Review for Breast Cancer
Liquid Biopsy by Application - Diagnostics, Prognostics and
Risk Assessment Markets - Independent Analysis of Annual Sales
in US$ for Years 2012 through 2019 and % CAGR

Table 121: Rest of Europe 15-Year Perspective for Breast Cancer
Liquid Biopsy by Application - Percentage Breakdown of Value
Sales for Diagnostics, Prognostics and Risk Assessment for the
Years 2012, 2021 & 2027

Table 122: Rest of Europe Recent Past, Current & Future
Analysis for Breast Cancer Liquid Biopsy by Circulating
Biomarker - Circulating Tumor Cells, Extracellular Vesicles and
Circulating Tumor DNA - Independent Analysis of Annual Sales in
US$ for the Years 2020 through 2027 and % CAGR

Table 123: Rest of Europe Historic Review for Breast Cancer
Liquid Biopsy by Circulating Biomarker - Circulating Tumor
Cells, Extracellular Vesicles and Circulating Tumor DNA Markets -
Independent Analysis of Annual Sales in US$ for Years 2012
through 2019 and % CAGR

Table 124: Rest of Europe 15-Year Perspective for Breast Cancer
Liquid Biopsy by Circulating Biomarker - Percentage Breakdown
of Value Sales for Circulating Tumor Cells, Extracellular
Vesicles and Circulating Tumor DNA for the Years 2012, 2021 &
2027

ASIA-PACIFIC
Breast Cancer Liquid Biopsy Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
Table 125: Asia-Pacific Recent Past, Current & Future Analysis
for Breast Cancer Liquid Biopsy by Product & Service - Reagent
Kits, Instruments and Services - Independent Analysis of Annual
Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 126: Asia-Pacific Historic Review for Breast Cancer
Liquid Biopsy by Product & Service - Reagent Kits, Instruments
and Services Markets - Independent Analysis of Annual Sales in
US$ for Years 2012 through 2019 and % CAGR

Table 127: Asia-Pacific 15-Year Perspective for Breast Cancer
Liquid Biopsy by Product & Service - Percentage Breakdown of
Value Sales for Reagent Kits, Instruments and Services for the
Years 2012, 2021 & 2027

Table 128: Asia-Pacific Recent Past, Current & Future Analysis
for Breast Cancer Liquid Biopsy by Application - Diagnostics,
Prognostics and Risk Assessment - Independent Analysis of
Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 129: Asia-Pacific Historic Review for Breast Cancer

Please contact our Customer Support Center to get the complete Table of Contents

Methodology

Our market research methodology is designed to provide the clients with comprehensive and accurate information on various industries and markets. It includes data collection, primary interviews, macro-economic factor analysis, country-level data analysis etc.

The data is gathered from a wide range of sources, including industry reports, government statistics, and company financials. This data is then analyzed and cross-referenced to ensure its accuracy and reliability. Next, primary interviews are conducted with industry experts and key stakeholders to gather their insights and perspectives on the market. This information is then combined with the data collected to provide a complete picture of the market. Macro-economic factor analysis is also carried out to understand the impact of external factors on the market. Finally, country-level data analysis is performed to understand the market dynamics in specific regions and countries.

Reportlinker's market research methodology is designed to provide clients with a clear understanding of the market, its trends, and its future potential.